Olmesartan medoxomil: current status of its use in monotherapy

References

• BrennerBMCooper medeZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med2001345861911565518
   PubMed Web of Science ®Google Scholar
• BrunnerHArakawaKAntihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goalsClin Drug Invest2005in press
   Web of Science ®Google Scholar
• BrunnerHRExperimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular diseaseAm J Cardiol2001873C9C
   PubMed Web of Science ®Google Scholar
• BrunnerHRThe new oral angiotensin II antagonist olmesartan medoxomil: a concise overviewJ Hum Hypertens200216Suppl 2S131611967728
   PubMedGoogle Scholar
• BrunnerHRClinical efficacy and tolerability of olmesartanClin Ther200426Suppl AA283215291377
   PubMedGoogle Scholar
• BrunnerHRNussbergerJWaeberBControl of vascular tone by renin and angiotensin in cardiovascular diseaseEur Heart J199314Suppl I149538293766
   PubMedGoogle Scholar
• BrunnerHRStumpeKOJanuszewiczAAntihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertensionClin Drug Invest20032341930
   PubMed Web of Science ®Google Scholar
• BurnierMBrunnerHRAngiotensin II receptor antagonistsLancet20003556374510696996
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA200328925607212748199
   PubMed Web of Science ®Google Scholar
• ChrysantSGMarburyTCRobinsonTDAntihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertensionJ Hum Hypertens2003174253212764406
   PubMed Web of Science ®Google Scholar
• CohenMCRohtlaKMLaveryCEMeta-analysis of the morning excess of acute myocardial infarction and sudden cardiac deathAm J Cardiol1997791512169185643
   PubMed Web of Science ®Google Scholar
• ConlinPRGerthWCFoxJFour-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classesClin Ther2001231999201011813934
   PubMed Web of Science ®Google Scholar
• DestroMScabrosettiRVanasiaAComparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoringAdv Ther200522324315943220
   PubMed Web of Science ®Google Scholar
• [ESH–ESC] European Society of Hypertension–European Society of Cardiology2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertensionJ Hypertens200321610115312777938
   PubMed Web of Science ®Google Scholar
• EwaldSNickenigGBöhmMOlmebest-study: reduction of blood pressure in the treatment of patients with mild-to-moderate essential hypertension - interim analysis of the German sub studyAm J Hypertens2005182
   Web of Science ®Google Scholar
• FletcherAEPalmerAJBulpittCJCough with angiotensin converting enzyme inhibitors: how much of a problem?J Hypertens Suppl199412S4377965265
   PubMedGoogle Scholar
• FliserDBuchholzKHallerHAntiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammationCirculation20041101103715313950
   PubMed Web of Science ®Google Scholar
• FliserDWagnerKKLoosAChronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetesJ Am Soc Nephrol20051611354015716329
   PubMed Web of Science ®Google Scholar
• HallerHVibertiGMimranAPreventing microalbuminuria in patients with diabetes - rationale and design of the Randomised Olmesartan And Diabetes MicroAlbuminuria Prevention (ROADMAP) StudyJ Hypertens2006in press
   Web of Science ®Google Scholar
• HaslerCNussbergerJMaillardMSustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitorClin Pharmacol Ther2005785501716321616
   PubMed Web of Science ®Google Scholar
• KoikeHNew pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonistAm J Cardiol200187Suppl 8A33C36C
   PubMed Web of Science ®Google Scholar
• KoikeHSadaTMizunoMIn vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonistJ Hypertens Suppl200119Suppl 1S31411451212
   PubMedGoogle Scholar
• LewingtonSClarkeRQizilbashNAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236019031312493255
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013458516011565517
   PubMed Web of Science ®Google Scholar
• MaillardMPWurznerGNussbergerJComparative angiotensin II receptor blockade in healthy volunteers: the importance of dosingClin Pharmacol Ther200271687611823759
   PubMed Web of Science ®Google Scholar
• MazzolaiLBurnierMComparative safety and tolerability of angiotensin II receptor antagonistsDrug Saf199921233310433351
   PubMed Web of Science ®Google Scholar
• MengdenTEwaldSKaufmannSTelemonitoring of blood pressure self measurement in the OLMETEL studyBlood Press Monit20049321515564988
   PubMed Web of Science ®Google Scholar
• MizunoMSadaTIkedaMPharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonistEur J Pharmacol199528518188566137
   PubMed Web of Science ®Google Scholar
• MogensenCEDiabetic renal disease in patients with type 2 diabetes mellitus: new strategies for prevention and treatmentTreat Endocrinol2002131115765616
   PubMedGoogle Scholar
• MullerJEStonePHTuriZGCircadian variation in the frequency of onset of acute myocardial infarctionN Engl J Med19853131315222865677
   PubMed Web of Science ®Google Scholar
• NeutelJMClinical studies of CS-866, the newest angiotensin II receptor antagonistAm J Cardiol20018737C43C
   PubMed Web of Science ®Google Scholar
• NussbergerJKoikeHAntagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomilClin Ther200426Suppl AA122015291375
   PubMedGoogle Scholar
• OparilSWilliamsDChrysantSGComparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertensionJ Clin Hypertens (Greenwich)200132839131811588406
   PubMedGoogle Scholar
• ParvingHHLehnertHBrochner-MortensenJThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med2001345870811565519
   PubMed Web of Science ®Google Scholar
• PuchlerKLaiesPStumpeKOBlood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonistJ Hypertens Suppl200119s41811451214
   PubMedGoogle Scholar
• PuchlerKNussbergerJLaeisPBlood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patientsJ Hypertens19971512 Pt 21809129488244
   PubMed Web of Science ®Google Scholar
• Sankyo Pharma GmbH2002 Data on file (integrated summary of efficacy)
   Google Scholar
• ScholzeJEwaldSOLMEPAS – STUDY: Olmesartan medoxomil for the treatment of hypertension under daily-practice conditions – results of a post-authorization study2005Berlin, GermanyDeutsche Hypertonie Ligatagung
   Google Scholar
• SchwochoLRMasonsonHNPharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjectsJ Clin Pharmacol2001415152711361048
   PubMed Web of Science ®Google Scholar
• SimonsWRComparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartanPharmacoeconomics200321617412484804
   PubMed Web of Science ®Google Scholar
• SmithDHDubielRJonesMUse of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartanAm J Cardiovasc Drugs20055415015631537
   PubMedGoogle Scholar
• StumpeKOOlmesartan compared with other angiotensin II receptor antagonists: head-to-head trialsClin Ther200426Suppl AA33715291378
   PubMedGoogle Scholar
• StumpeKOLudwigMAntihypertensive efficacy of olmesartan compared with other antihypertensive drugsJ Hum Hypertens200216Suppl 2S24811967729
   PubMedGoogle Scholar
• TakemotoMEgashiraKTomitaHChronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesisHypertension199730162179403592
   PubMed Web of Science ®Google Scholar
• TomitaHEgashiraKOharaYEarly induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in ratsHypertension19983227399719054
   PubMed Web of Science ®Google Scholar
• UsuiMEgashiraKTomitaHImportant role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in ratsCirculation20001013051010645927
   PubMed Web of Science ®Google Scholar
• Van MieghemWA multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension [abstract]J Hypertens200119S1523
   Google Scholar
• VleemingWvan AmsterdamJGStrickerBHACE inhibitor-induced angioedema. Incidence, prevention and managementDrug Saf199818171889530537
   PubMed Web of Science ®Google Scholar
• WarnerGTJarvisBOlmesartan medoxomilDrugs200262134553 discussion, 1354-612076183
   PubMed Web of Science ®Google Scholar
• WehlingMCan the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?Clin Ther200426Suppl AA21715291376
   PubMedGoogle Scholar
• WilliamsPAA multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus captopril in patients with mild to moderate essential hypertension [abstract]J Hypertens200119suppl 2S300
   Google Scholar
• YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet20043649375215364185
   PubMed Web of Science ®Google Scholar